SCHEMBL5605570

SCHEMBL5605570

CN(C(=O)CN1CCN(C(=O)CCCC(=O)O)CC1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.57
TACR1 P25103 1/20 0.51
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
TSHR P16473 2/20 0.46
HTR1A P08908 2/20 0.46
HTR7 P34969 2/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
AURKA O14965 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SIGMAR1 Q99720 2/20 0.43
GAA P10253 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CACNA2D1 P54289 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866919 0.80 DRD4 (0.57) DRD4CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL12359040 0.79 DRD4 (0.67) DRD4ALDH1A1SMN1; SMN2KDM4ETSHR
SCHEMBL10282320 0.79 DRD4 (0.67) DRD4TACR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3577293 0.78 DRD4 (0.64) DRD4ALDH1A1KDM4EMAPTLMNA
SCHEMBL12322238 0.77 DRD4 (0.61) DRD4TACR1ALDH1A1KDM4ETSHR
SCHEMBL5555256 0.77 KDM4E (0.51) ALDH1A1SMN1; SMN2KDM4ELMNANPSR1
SCHEMBL654170 0.76 DRD4 (0.63) DRD4ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL13015452 0.76 DRD4 (0.60) DRD4TACR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL19231633 0.76 DRD4 (0.62) DRD4ALDH1A1AURKACACNA2D1CACNA1B
SCHEMBL10244827 0.76 DRD4 (0.62) DRD4TACR1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166594-B2 Antibacterial activity AVENTIS PHARMA S.A. (FR) 2007-01-23 US disclosed
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. 2003-08-07 US disclosed
US-6569854-B1 Virginamycins AVENTIS PHARMA S.A. (FR) 2003-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them MRPL21, ABHD5, APEH DRD4 3424/4885TACR1 2628/4885ALDH1A1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.